TSE:APSAptose Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$9.47 +0.06 (+0.64 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's RangeC$9.10Now: C$9.47▼C$9.6950-Day RangeC$9.41MA: C$10.68▼C$12.0752-Week RangeC$2.37Now: C$9.47▼C$12.62Volume77,600 shsAverage Volume98,952 shsMarket CapitalizationC$722.31 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Aptose Biosciences. Previous Next 2.8 Community Rank Outperform VotesAptose Biosciences has received 201 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAptose Biosciences has received 164 “underperform” votes. (Add your “underperform” vote.)Community SentimentAptose Biosciences has received 55.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote “Outperform” if you believe APS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aptose Biosciences are expected to grow in the coming year, from C($0.50) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -17.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -17.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptose Biosciences has a P/B Ratio of 8.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.69 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:APS Previous Symbol CUSIPN/A CIKN/A Webaptose.com Phone+1-647-4799828Debt Debt-to-Equity Ratio1.63 Current Ratio20.56 Quick Ratio20.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$1.08 per share Price / Cash Flow8.77 Book ValueC$1.14 per share Price / Book8.28Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees31 Outstanding Shares76,274,000Market CapC$722.31 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable TSX:APS Rates by TradingView Receive APS News and Ratings via Email Sign-up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter. Aptose Biosciences (TSE:APS) Frequently Asked Questions How has Aptose Biosciences' stock been impacted by COVID-19 (Coronavirus)? Aptose Biosciences' stock was trading at C$7.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APS stock has increased by 19.4% and is now trading at C$9.47. View which stocks have been most impacted by Coronavirus. When is Aptose Biosciences' next earnings date? Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aptose Biosciences. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (TSE:APS) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.06. View Aptose Biosciences' earnings history. Has Aptose Biosciences been receiving favorable news coverage? Press coverage about APS stock has been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aptose Biosciences earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutAptose Biosciences. Who are some of Aptose Biosciences' key competitors? Some companies that are related to Aptose Biosciences include Viela Bio (VIE), Genus (GNS), Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Trillium Therapeutics (TRIL), PureTech Health (PRTC), Bellus Health (BLU), CEL-SCI (CVM), Oxford BioMedica (OXB), Cel-Sci (CVM) and SIGA Technologies (SIGA). View all competitors. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), Altagas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD). Who are Aptose Biosciences' key executives? Aptose Biosciences' management team includes the following people: Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell, Chief Medical Officer (Age 73)Mr. Peter Murray, Director of Clinical Devel. What is Aptose Biosciences' stock symbol? Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS." How do I buy shares of Aptose Biosciences? Shares of APS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Aptose Biosciences' stock price today? One share of APS stock can currently be purchased for approximately C$9.47. How big of a company is Aptose Biosciences? Aptose Biosciences has a market capitalization of C$722.31 million. Aptose Biosciences employs 31 workers across the globe. What is Aptose Biosciences' official website? The official website for Aptose Biosciences is aptose.com. How can I contact Aptose Biosciences? Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The biotechnology company can be reached via phone at +1-647-4799828. This page was last updated on 6/6/2020 by MarketBeat.com Staff
